MX342474B - Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos. - Google Patents

Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.

Info

Publication number
MX342474B
MX342474B MX2013012947A MX2013012947A MX342474B MX 342474 B MX342474 B MX 342474B MX 2013012947 A MX2013012947 A MX 2013012947A MX 2013012947 A MX2013012947 A MX 2013012947A MX 342474 B MX342474 B MX 342474B
Authority
MX
Mexico
Prior art keywords
cells
isolation
express
cell populations
immunoregulatory activity
Prior art date
Application number
MX2013012947A
Other languages
English (en)
Inventor
Angel Gonzalez De La Peña Manuel
Büscher Dirk
Delgado Mora Mario
Original Assignee
Cellerix Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX342474(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellerix Sl filed Critical Cellerix Sl
Publication of MX342474B publication Critical patent/MX342474B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a el uso de una población de células aisladas de tejido adiposo para la preparación o generación in vitro de células T reguladora (T-reg), en donde las células de dicha población de células: a) no expresan marcadores específicos para células presentadoras de antígeno (CPA, b) no expresan indolamin-2,3-dioxigenasa (IDO) de manera constitutiva, c) expresan IDO tras la estimulación con interferón-gamma (IFN-?), y d) presentan capacidad para diferenciarse en al menos dos linajes celulares.
MX2013012947A 2005-09-23 2006-09-22 Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos. MX342474B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05077186 2005-09-23
PCT/EP2006/009244 WO2007039150A2 (en) 2005-09-23 2006-09-22 Cell populations having immunoregulatory activity, method for isolation and uses

Publications (1)

Publication Number Publication Date
MX342474B true MX342474B (es) 2016-09-30

Family

ID=37708240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012947A MX342474B (es) 2005-09-23 2006-09-22 Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.

Country Status (19)

Country Link
US (5) US20090130067A1 (es)
EP (4) EP1926813B2 (es)
JP (2) JP5925408B2 (es)
KR (2) KR20080048555A (es)
CN (2) CN107723274B (es)
AU (1) AU2006299144A1 (es)
CA (2) CA2953782C (es)
CY (1) CY1117972T1 (es)
DK (1) DK1926813T4 (es)
ES (2) ES2751692T3 (es)
HU (1) HUE030503T2 (es)
IL (3) IL190363A0 (es)
LT (1) LT1926813T (es)
MX (1) MX342474B (es)
PL (1) PL1926813T5 (es)
PT (1) PT1926813T (es)
SG (3) SG165418A1 (es)
SI (1) SI1926813T2 (es)
WO (1) WO2007039150A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
HUE051267T2 (hu) 2005-12-13 2021-03-01 Harvard College Sejttranszplantációs állványok
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
SG191701A1 (en) 2008-03-28 2013-07-31 Stemcyte Inc Treatment of brain damage using umbilical cord blood cells
EP3320912B1 (en) * 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
AU2009201915C1 (en) 2008-08-22 2015-02-26 Regeneus Ltd Therapeutic methods
EP2204442A1 (en) * 2008-10-01 2010-07-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method of enriching stem cells in culture
GB0820397D0 (en) 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
EP3150703A1 (en) 2009-07-09 2017-04-05 TiGenix, S.A.U. Cells for use in a method for treating inflammatory and/or immune disorders
CA2768552A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
GB0918615D0 (en) 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
WO2012095743A2 (en) 2011-01-12 2012-07-19 Cellerix Sa Methods and compositions for use in intralymphatic cellular therapies
WO2012123401A1 (en) * 2011-03-11 2012-09-20 Tigenix, S.A. Cell populations having immunoregulatory activity, method for isolation and uses
CN103619177A (zh) * 2011-04-25 2014-03-05 南加州大学 通过抑制干扰素-γ和肿瘤坏死因子-α来改善组织再生的方法和组合物
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
KR20140071277A (ko) 2011-05-19 2014-06-11 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
EP3013943B1 (en) 2013-06-25 2019-04-10 TiGenix, S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
CA2919374C (en) 2013-07-30 2019-12-03 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
HUE054471T2 (hu) 2014-04-01 2021-09-28 Rubius Therapeutics Inc Immunmodulációs módszerek és készítmények
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
EP3160480B1 (en) 2014-06-30 2020-09-09 TiGenix, S.A.U. Mesenchymal stromal cells for treating rheumatoid arthritis
MX381544B (es) 2014-06-30 2025-03-12 Takeda Pharmaceuticals Co Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
JP2016017068A (ja) * 2014-07-10 2016-02-01 国立大学法人金沢大学 脂肪組織由来間質細胞群を含む消化管炎症治療剤
KR101675521B1 (ko) * 2014-07-11 2016-11-17 대한민국 인돌아민 2,3-디옥시게나아제를 이용하여 인터페론-감마의 발현을 조절하는 방법
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
CA3177726A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
WO2017144552A1 (en) 2016-02-22 2017-08-31 Centauri Biotech. S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
CA3032505A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
WO2018170335A1 (en) 2017-03-15 2018-09-20 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
US20210008120A1 (en) 2018-03-13 2021-01-14 Oxacell Ag Cell products with improved stability and uses thereof
CA3103043A1 (en) 2018-06-15 2019-12-19 Luis Marinas Pardo Pharmaceutical composition for dermatology and uses thereof
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
KR20210149148A (ko) * 2019-05-21 2021-12-08 이엠오 바이오메디슨 코퍼레이션 면역-관련 질환 치료에서의 중간엽 줄기 세포의 용도
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
EP4096720A2 (en) * 2020-01-30 2022-12-07 ModernaTX, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
KR102438419B1 (ko) * 2021-12-01 2022-09-01 메디포스트(주) Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145770A (en) 1990-06-04 1992-09-08 Biosurface Technology, Inc. Cryopreservation of cultured epithelial sheets
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
CA2192103C (en) 1994-06-06 2002-02-05 Arnold I. Caplan Biomatrix for tissue regeneration
ES2351082T3 (es) 1997-12-02 2011-01-31 Artecel Sciences, Inc. Diferenciación de células estromales adiposas en osteoblastos y sus usos.
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
ATE265220T1 (de) 1998-02-04 2004-05-15 Gen Hospital Corp Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
US6797269B2 (en) * 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
RU2306335C2 (ru) 1999-03-10 2007-09-20 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Стволовые клетки и решетки, полученные из жировой ткани
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20030082152A1 (en) 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
US7670628B2 (en) 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US7078232B2 (en) 1999-08-19 2006-07-18 Artecel, Inc. Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
EP1257282A4 (en) 1999-12-06 2003-05-02 Gen Hospital Corp PANCREATIC STEM CELLS AND THEIR USE IN TRANSPLANTATION
JP4680483B2 (ja) 2001-02-23 2011-05-11 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織および臓器の治療および修復に用いるための幹細胞マトリックスの迅速な調製方法
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
BR0214029A (pt) * 2001-11-09 2005-04-19 Artecel Sciences Inc Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
JP2005528082A (ja) * 2001-12-18 2005-09-22 モンドバイオテック・ラボラトリーズ・アンスタルト 間質性肺疾患の治療を向上させるためのインターフェロンγ又はパーフェニドンと分子診断薬との新規医薬組成物
AU2003225791A1 (en) 2002-03-15 2003-09-29 Department Of Veterans Affairs, Rehabilitation R And D Service Methods and compositions for directing cells to target organs
DE60318706T2 (de) 2002-06-14 2009-04-30 Cartela R & D Ab Marker für stammzellen und dessen verwendung
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20040101959A1 (en) 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
US7494812B2 (en) * 2003-04-01 2009-02-24 University Of Southern California Generation of human regulatory T cells by bacterial toxins for the treatment of inflammatory disorders
ATE482725T1 (de) 2003-04-01 2010-10-15 Us Dept Of Veteran S Affaires Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen.
ES2265199B1 (es) * 2003-06-12 2008-02-01 Cellerix, S.L. Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones.
ES2552226T3 (es) 2003-06-27 2015-11-26 DePuy Synthes Products, Inc. Reparación y regeneración de cartílago y hueso utilizando células derivadas posparto
WO2005035738A1 (en) 2003-10-07 2005-04-21 Biomaster Inc. Cell differentiation of adipose-derived precursor cells
US9631176B2 (en) 2003-11-04 2017-04-25 Biomaster, Inc. Method for preparing stem cells from fat tissue
WO2005062857A2 (en) 2003-12-24 2005-07-14 The Trustees Of Columbia University In The City Of New York Creation of a biological atrioventricular bypass to compensate for atrioventricular block
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性ｔ細胞は自己免疫を抑制する
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
RU2252252C1 (ru) 2004-04-09 2005-05-20 Тепляшин Александр Сергеевич Способ выделения мезенхимальных стволовых клеток
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
ES2264862B8 (es) 2004-08-25 2017-01-20 Cellerix, S.L. Biomaterial para sutura.
US7732126B2 (en) 2004-09-03 2010-06-08 University Of Maryland, Baltimore Integrin CD18 is a novel stromal stem cell marker and functions to promote osteogenesis
WO2006110582A1 (en) 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2008036374A2 (en) 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
EP2191835A4 (en) 2007-09-07 2011-12-14 Japan Chem Res THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS
KR20140107677A (ko) 2007-09-19 2014-09-04 플루리스템 리미티드 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도
KR20100076031A (ko) 2007-10-17 2010-07-05 티엑셀 Ｔｒ１ 세포, 중간엽 줄기 세포 및 이들의 용도
GB0814249D0 (en) 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
ES2345867B1 (es) 2009-04-03 2011-07-28 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Celulas madre multipotentes derivadas de estroma de mesenterio.
EP3150703A1 (en) 2009-07-09 2017-04-05 TiGenix, S.A.U. Cells for use in a method for treating inflammatory and/or immune disorders
WO2012095743A2 (en) 2011-01-12 2012-07-19 Cellerix Sa Methods and compositions for use in intralymphatic cellular therapies
WO2012123401A1 (en) 2011-03-11 2012-09-20 Tigenix, S.A. Cell populations having immunoregulatory activity, method for isolation and uses
US20140134140A1 (en) 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
EP3581932A1 (en) 2013-03-15 2019-12-18 TiGenix, S.A.U. Lymphocyte biomarkers for determining the clinical response to cell therapy
EP3013943B1 (en) 2013-06-25 2019-04-10 TiGenix, S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Also Published As

Publication number Publication date
CA2953782A1 (en) 2007-04-12
EP3184631A1 (en) 2017-06-28
JP6089004B2 (ja) 2017-03-01
US20170296592A1 (en) 2017-10-19
EP1926813B2 (en) 2019-05-22
ES2751692T3 (es) 2020-04-01
JP2014221045A (ja) 2014-11-27
SG165418A1 (en) 2010-10-28
IL246494B (en) 2021-09-30
KR20080048555A (ko) 2008-06-02
WO2007039150A3 (en) 2007-08-23
PT1926813T (pt) 2016-09-06
EP1926813B1 (en) 2016-06-08
WO2007039150A2 (en) 2007-04-12
IL228670A (en) 2017-06-29
IL246494A0 (en) 2016-08-31
ES2589311T5 (es) 2020-02-14
US20090130067A1 (en) 2009-05-21
JP2009508507A (ja) 2009-03-05
EP3184630A1 (en) 2017-06-28
IL190363A0 (en) 2011-08-01
SI1926813T1 (sl) 2016-10-28
EP2340847A2 (en) 2011-07-06
KR101536239B1 (ko) 2015-07-13
DK1926813T4 (da) 2019-08-19
CN101313062A (zh) 2008-11-26
IL228670A0 (en) 2013-12-31
SI1926813T2 (sl) 2019-11-29
AU2006299144A1 (en) 2007-04-12
EP3184631B1 (en) 2020-08-12
DK1926813T3 (en) 2016-09-19
PL1926813T5 (pl) 2019-11-29
CA2953782C (en) 2023-09-12
EP2340847B1 (en) 2025-11-05
EP1926813A2 (en) 2008-06-04
EP2340847A3 (en) 2016-11-09
US20170296593A1 (en) 2017-10-19
HUE030503T2 (en) 2017-05-29
US20220313742A1 (en) 2022-10-06
SG10201400793RA (en) 2014-08-28
CN107723274B (zh) 2021-05-07
CY1117972T1 (el) 2017-05-17
JP5925408B2 (ja) 2016-05-25
PL1926813T3 (pl) 2017-01-31
ES2589311T3 (es) 2016-11-11
CA2623353A1 (en) 2007-04-12
US9943550B2 (en) 2018-04-17
SG10202001007TA (en) 2020-03-30
EP3184630B1 (en) 2019-07-17
CA2623353C (en) 2017-02-21
KR20140003631A (ko) 2014-01-09
US12186344B2 (en) 2025-01-07
LT1926813T (lt) 2016-11-10
CN107723274A (zh) 2018-02-23
US20150224146A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
MX342474B (es) Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
BR112014001075A2 (pt) sonda, seu uso, método in vitro para associar uma sonda com um alvo e kit
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
BR112016014488A2 (pt) Meio para cultura celular
ECSP13012692A (es) Compuestos tricíclicos inhibidores de la pi3k y métodos de uso
CO6761392A2 (es) Administración de proteínas a partir de microportadores de células madre
ES2534304T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
BRPI0417194A (pt) células-tronco
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
ES2523998T3 (es) Método de aislamiento de citoblastos dérmicos
BR112014018524A2 (pt) derivados de pirimido [4,5-b]indol e métodos de utilização dos mesmos na expansão de células-tronco hematopoiéticas, composição farmacêutica e kits
BR0312764A (pt) Cardiomiócitos funcionais originados de células-tronco embrionárias humanas
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
AR094389A1 (es) USO DE INHIBIDORES DE iNOS PARA AUMENTAR EL RENDIMIENTO VÍRICO EN CULTIVOS
MX383334B (es) Celulas discogenicas aisladas, metodos de uso, y metodos de preparacion de las mismas a partir de tejido de mamifero.
RU2014146170A (ru) Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
ES2626639T3 (es) Medicamento o composición dermatológica que contiene un extracto peptídico de aguacate destinado al tratamiento y a la prevención del prurito interno
AR087980A1 (es) Actividad de dnasa endogena para reducir el contenido de adn
ES2498926T3 (es) N-hidroxi-benzamidas para el tratamiento del cáncer
ATE544848T1 (de) Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)
CL2010000774A1 (es) Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso.
AR039186A1 (es) Celulas madre indiferenciadas programables de origen monocitaro, su obtencion y uso